Premium Grade | UK Supply | Research Peptide | COA Certified | >99% Purity | Worldwide Delivery

(Heptapeptide, 7 amino acids)

Brief Summary

PE-22-28 is a synthetic heptapeptide studied in laboratory settings for its interaction with the TREK-1 potassium channel, also identified as KCNK2 or K2P2.1. Derived from research involving shortened analogues of the sortilin-associated peptide spadin, PE-22-28 contains seven amino acids and is investigated as a sequence-specific TREK-1 channel inhibitor. Research has focused particularly on neuronal excitability, potassium-channel activity, synaptic signalling and neurogenesis-associated pathways. PE-22-28 has also been examined in preclinical models involving cellular stress, neuronal survival markers and neural pathway regulation. Within scientific research catalogues, PE-22-28 is valued for in vitro and preclinical investigation involving ion-channel biology, neuroactive signalling, membrane-potential regulation and comparative spadin analogue analysis. Its defined seven-amino-acid sequence supports structured laboratory study, analytical characterisation and reproducible peptide research within professional scientific environments.

Product Overview

PE-22-28 is a laboratory-grade synthetic peptide developed for controlled research into TREK-1 channel activity, neuronal signalling and membrane-associated cellular communication. Its amino-acid sequence, Gly–Val–Ser–Trp–Gly–Leu–Arg, is commonly abbreviated as GVSWGLR. TREK-1 belongs to the two-pore-domain potassium-channel family and contributes to background potassium movement, resting membrane potential and cellular excitability. PE-22-28 has been examined as a shortened spadin-related sequence capable of inhibiting TREK-1 activity in experimental systems. This allows researchers to investigate how potassium-channel modulation influences neuronal firing patterns, intracellular signalling and synaptic pathway responses. Its defined composition, compact molecular structure and reproducible characteristics support controlled investigation into ion-channel pharmacology, neural cell communication and structure-activity relationships.

Scientific Background

From a molecular science perspective, PE-22-28 is studied as a potent inhibitor of TREK-1 channels. These channels regulate background potassium conductance across cellular membranes and contribute to the maintenance of resting membrane potential. Experimental inhibition of TREK-1 can alter membrane polarisation and influence the electrical responsiveness of neural cells. PE-22-28 was identified through research comparing shortened spadin analogues to determine the minimum sequence required for TREK-1 interaction. Laboratory studies have examined its influence on channel activity, neuronal excitability, neurogenesis-associated markers and intracellular pathways connected with neural plasticity. Additional research has investigated cellular survival signalling and responses to experimentally induced neural stress. PE-22-28 therefore provides a compact molecular tool for examining potassium-channel regulation, spadin-derived peptide activity and the relationship between membrane conductance and neuroactive cellular signalling.

Research Applications

PE-22-28 is applied in laboratory research across peptide science, neurobiology, ion-channel pharmacology and cellular signalling. Researchers use the peptide to examine TREK-1 inhibition, potassium-channel activity, resting membrane-potential regulation and neuronal excitability under controlled experimental conditions. Additional research applications include analysis of neural plasticity markers, neurogenesis-associated pathways, synaptic communication and cellular responses to experimentally induced stress. PE-22-28 may also be used in comparative studies involving spadin and other shortened peptide analogues to determine how sequence changes influence channel selectivity and molecular stability. Its seven-residue structure supports research into peptide simplification, sequence-specific binding, molecular recognition and structure-activity relationships. These applications contribute to a broader understanding of two-pore-domain potassium channels and their relationship with neuroactive cellular communication. PE-22-28 is supplied as a research compound for analytical, in vitro and controlled preclinical investigation only.

Technical Specifications

Contents: 10mg PE-22-28
Form: Lyophilised powder
Purity: >99% (HPLC Verified)
Molecular Formula: C₃₅H₅₅N₁₁O₉
Molecular Weight: 773.89 g/mol
Sequence: Glycine–Valine–Serine–Tryptophan–Glycine–Leucine–Arginine
Peptide Length: 7 amino acids
pH Range: 6.0-7.5
Storage: Store between 1°C and 5°C 

Note: Reconstitute with Bacteriostatic Water

Explore Related Research Compounds
Continue exploring related laboratory research products from BioPlex Peptides.

View Cartalax 20mg Research Compound ⟶
View Cardiogen 20mg Research Compound ⟶
View DSIP 5mg Research Compound ⟶

Research Preparation and Storage
Access BioPlex solutions, calculation tools and storage guidance for accurate and consistent laboratory preparation.

View Reconstitution Solutions ⟶
Use the Peptide Reconstitution Calculator ⟶
Read the Peptide Types and Storage Guide ⟶

Explore Related Research Articles
Continue your research with detailed BioPlex articles covering compound structures, scientific mechanisms and laboratory research pathways.

Disclaimer

For research purposes only. Not for human consumption